Phase I Clinical Trial of R327 I.V. - 6000mg Complete

® ® ® serious adverse effects among 10 healthy male subjects. An Independent Safety Committee is reviewing the latest patient dosing data and is expected to recommend go ahead with Cohort 8 dosing of R327. The Company notes 6,000mg as being broadly efficacious in animal models previously; with following phases (efficacy) necessary to fully determine with preparations well underway. James Graham, C